Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 25;61(16):6193-6208.
doi: 10.1021/acs.inorgchem.2c00358. Epub 2022 Apr 8.

Photocatalytic Aerobic Dehydrogenation of N-Heterocycles with Ir(III) Photosensitizers Bearing the 2(2'-Pyridyl)benzimidazole Scaffold

Affiliations

Photocatalytic Aerobic Dehydrogenation of N-Heterocycles with Ir(III) Photosensitizers Bearing the 2(2'-Pyridyl)benzimidazole Scaffold

Igor Echevarría et al. Inorg Chem. .

Abstract

Photoredox catalysis constitutes a very powerful tool in organic synthesis, due to its versatility, efficiency, and the mild conditions required by photoinduced transformations. In this paper, we present an efficient and selective photocatalytic procedure for the aerobic oxidative dehydrogenation of partially saturated N-heterocycles to afford the respective N-heteroarenes (indoles, quinolines, acridines, and quinoxalines). The protocol involves the use of new Ir(III) biscyclometalated photocatalysts of the general formula [Ir(C^N)2(N^N')]Cl, where the C^N ligand is 2-(2,4-difluorophenyl)pyridinate, and N^N' are different ligands based on the 2-(2'-pyridyl)benzimidazole scaffold. In-depth electrochemical and photophysical studies as well as DFT calculations have allowed us to establish structure-activity relationships, which provide insights for the rational design of efficient metal-based dyes in photocatalytic oxidation reactions. In addition, we have formulated a dual mechanism, mediated by the radical anion superoxide, for the above-mentioned transformations.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Synthesis route and molecular structures of ligands L1L5 and complexes [Ir1]Cl–[Ir5]Cl. Complexes were obtained as racemic mixtures but only Λ enantiomers are shown.
Figure 2
Figure 2
ORTEP diagrams for the molecular structures of (Λ)-[Ir1]+, (Λ)-[Ir3]+, (Λ)-[Ir4]+ and (Λ)-[Ir5]+ obtained by X-ray diffraction. Thermal ellipsoids are shown at the 30% probability level. The Δ enantiomers, the H atoms, the Cl or PF6 counterions, and the solvent molecules (MeOH for rac-[Ir1]Cl) have been omitted for the sake of clarity.
Figure 3
Figure 3
Schematic representation of the energies and the isovalue contour pictures calculated for the frontier molecular orbitals of [Ir(dfppy)2(bpy)]+, [2]+, and [Ir3]+.
Figure 4
Figure 4
Energy diagram showing the calculated energy difference values between the lowest triplet excited state (T1) and the singlet ground state, keeping the geometry of the respective triplet (S0) for complexes [1]+, [2]+, and [Ir1]+[Ir5]+.
Figure 5
Figure 5
(a) Overlaid UV–vis absorption spectra of [Ir1]Cl[Ir5]Cl (10–5 M) in CH3CN at 25 °C along with the emission spectrum of the blue light used in the photocatalytic assays (left). (b) Overlaid emission spectra of of [Ir1]Cl[Ir5]Cl (10–5 M) in deoxygenated CH3CN at 25 °C upon excitation with λex = 405 nm (right).
Figure 6
Figure 6
Cyclic voltammograms of complexes [Ir1]Cl[Ir5]Cl in acetonitrile solution (5 × 10–4 M), using 0.1 M [nBu4N][PF6] as supporting electrolyte and recorded with scan rate of 0.10 V·s–1.
Figure 7
Figure 7
Latimer diagram for [Ir3]Cl, with redox potentials determined by CV and the emission energy calculated from the photoluminescence spectrum. The redox potentials for [Ir3]+ and its excited state [Ir3*]+ are given in V versus Fc+/Fc. E1/2(IrIV/IrIII*) = E1/2(IrIV/IrIII) – E1/2(IrIII*/IrIII) and E1/2(IrIII*/IrII) = E1/2(IrIII/IrII) + E1/2(IrIII*/IrIII). All the potential values are given as reduction potentials regardless the sense of the arrows for the quenching cycles.
Figure 8
Figure 8
Stern–Volmer quenching experiments. (a) Emission quenching of [Ir4]Cl (0.07 mM in CH3CN, 25 °C) upon incremental addition of substrate 3a (0.1–2 mM) under N2 and λir = 405 nm. (b) Stern–Volmer quenching plot, where I0 = PL intensity of [Ir4]Cl at [3a] = 0 mM; I = PL intensity of [Ir4]Cl at different [3a]; I0/I = 29.728 × [3a] + 1.0544; R2 = 0.9996.
Figure 9
Figure 9
Pathways A and B for the oxidative dehydrogenation of 3a in the presence of the new Ir(III) PCs. Steps (2), (3) and (4), (5) etc. from species A are common for both pathways.

Similar articles

Cited by

References

    1. Vitaku E.; Smith D. T.; Njardarson J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. J. Med. Chem. 2014, 57 (24), 10257–10274. 10.1021/jm501100b. - DOI - PubMed
    1. Kaushik N.; Kaushik N.; Attri P.; Kumar N.; Kim C.; Verma A.; Choi E. Biomedical Importance of Indoles. Molecules 2013, 18 (6), 6620–6662. 10.3390/molecules18066620. - DOI - PMC - PubMed
    1. Desai N. C.; Kotadiya G. M.; Trivedi A. R. Studies on Molecular Properties Prediction, Antitubercular and Antimicrobial Activities of Novel Quinoline Based Pyrimidine Motifs. Bioorg. Med. Chem. Lett. 2014, 24 (14), 3126–3130. 10.1016/j.bmcl.2014.05.002. - DOI - PubMed
    1. Man R.-J.; Jeelani N.; Zhou C.; Yang Y.-S. Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents. Anticancer. Agents Med. Chem. 2021, 21 (7), 825–838. 10.2174/1871520620666200516150345. - DOI - PubMed
    1. Fonte M.; Tassi N.; Gomes P.; Teixeira C. Acridine-Based Antimalarials—From the Very First Synthetic Antimalarial to Recent Developments. Molecules 2021, 26 (3), 600.10.3390/molecules26030600. - DOI - PMC - PubMed